Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors

Published:2023-12-16 Issue: Volume: Page:
ISSN:2366-1070
Container-title:Oncology and Therapy
language:en
Short-container-title:Oncol Ther

Author:

Chen Hong,Wen Yan,Zeng Yun,Lin Lie,Sun Bihong,Zhu Hongqian,He Huiqing,Wang Xiaotao,Zou Waiyi,Zheng Caifeng,Zheng Liling,Huang Jinxiong,Pang Liping,Huang Jixian,Zhang Yuming,Lin Haiqing,Liu Zelin,Zhu Wanshou,Wang Qiang,Zhou Xuan,Liu Xiaoli,Qu Hong,Liu Zhenfang,Du Xin,Xu Na^ORCID

Funder

Natural Science Foundation of Guangdong Province

Guangzhou Municipal Science and Technology Bureau

National Natural Science Foundation of China

the Open project of Yunnan Blood Disease Clinical Medical Center

the Key Basic Research Project of Guangzhou City-Basic and The Applied Basic Research Program of Science

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s40487-023-00255-2.pdf

Reference36 articles.

1. Keating N, Brooks G, Landrum M, et al. The oncology care model and adherence to oral cancer drugs: a difference-in-differences analysis. J Natl Cancer Inst. 2022;114(6):871–7.

2. White HE, Salmon M, Albano F, et al. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia. 2022;36(7):1834–42.

3. Atallah E, Schiffer CA, Radich JP, et al. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial. JAMA Oncol. 2021;7(1):42–50.

4. Inzoli E, Aroldi A, Piazza R, Gambacorti-Passerini C. Tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: eligibility criteria and predictors of success. Am J Hematol. 2022;97(8):1075–85.

5. Janssen L, Blijlevens N, Drissen M, et al. Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity. Haematologica. 2021;106(7):1876–82.